Follow us on:
Breaking News
August 5, 2026
Breaking News
Breaking News
Cytiva_CP_Leaderboard_0826

Tackling Combination Products’ Complexity and Testing Challenges

 
combination product testing

How sponsors can navigate sterility, microbiology, E&L, and regulatory expectations as combination products become more complex.
Play Now >>

Headlines

Breaking News

Piramal Pharma Solutions Expands Peptide API Facility

Adds new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India.

SPONSOR

The CGT Supply Chain Starts With Better Plasmid Manufacturing

Yield, purity, scalability. Learn how to optimize every stage of plasmid production for cell and gene therapy. Free webinar, August 27.

Breaking News
Collaborations & Alliances

Lilly, Amplia to Evaluate Combined Investigational Treatments for Advanced NSCLC

A Phase Ib/IIb clinical trial is testing safety and efficacy of this novel targeted therapy combination.

Breaking News
Promotions & Moves

FUJIFILM Biotechnologies Transitions Leadership

Maja Pedersen has been appointed President to drive next phase of operational growth.

SPONSOR

Stop Risk Before It Starts: Smarter CDMO Strategy

One-size CDMOs fail complex injectables. Discover how tailored fill-finish cuts risk, accelerates timelines, and safeguards your product from vial to patient.

Informa Market (UK)_CP_Box Ad_0826_0926

Breaking News
Collaborations & Alliances

Niagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate

Proprietary candidate NB4168 has been developed for treatment of ataxia telangiectasia.

SPONSOR

Ensure DSCSA Compliance with Confidence

Meet DSCSA requirements with a complete serialization platform delivering end-to-end visibility, traceability, and compliance support.

Global Insights_CP_Box Ad_0826
Featured Resources

Solution Center SPOTLIGHT

Pace Life Sciences

Pace® makes the world a safer, healthier place. We advance the science of our pharmaceutical and biopharmaceutical customers through the drug development process, from early-phase R&D through clinical trials and GMP commercial product support. For customers with in-house manufacturing and labs, we provide support through professional services.

 

Solution Center SPOTLIGHT

Abzena

Abzena is the leading end-to-end bioconjugate (ADC, AOC, & RDC) & complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development and manufacture of new treatments for patients. Let us help move your program forward faster.